

Option Table Decision Aid

For a patient with psoriatic arthritis—arthritis, enthesitis, and dactylitis dominant clinical phenotype.

| Medication options | Sulfasalazine | Methotrexate | Leflunomide | PDE4i Apremilast | JAK Inhibitor Tofacitinib | Anti-TNF Etanercept Adalimumab Infliximab Certolizumab Golimumab | T-cell modulation Abatacept | Anti IL-12/23i Ustekinumab | Anti IL-17 Secukinumab Ixekizumab* |
|---|--|---|---|--|---|--|---|--|---|
| Year of FDA approval | Off label (RA 1996) | Off label (RA 1976) | Off label (RA 1998) | 2014 | 2012 | 2004 and later (RA 1999) | 2017 (RA 2005) | 2013 (Psoriasis 2009) | 2015, 2017* |
| Administered via | Pill | Pill | Pill | Pill | Pill | Injection or infusion | Injection | Injection or infusion | Injection |
| Frequency | Twice daily | Once a week | Once daily | Twice daily | Once daily | Varied by agent | Once a week | Once a month after loading | Once a month after loading |
| Power to suppress arthritis (ACR 20) | 57 of 100 improve | 60 of 100 improve | 58 of 100 improve | 45 of 100 improve | 50 of 100 improve | 65 of 100 improve | 41 of 100 improve | 43 of 100 improve | 51-55 of 100 improve |
| Power to clear psoriasis (PASI 75%) | Unknown | 36 of 100 clear | 17 of 100 clear | 31 of 100 clear | 40 of 100 clear | 49-80 of 100 clear | 16 of 100 clear | 55 of 100 clear | 70 of 100 clear |
| Serious infection risk (events/100 patient years) | 0.5 in 100 | 2 in 100 | 3 in 100 | 0.5 in 100 | 3 in 100 | 5 in 100 | 3 in 100 | 3 in 100 | 1 in 100 |
| Other risks | liver test, blood counts | liver test, blood counts | liver test, blood counts | Upset stomach, weight, depression | liver test, blood counts, diverticulitis | Injection site reaction, immune reaction | Injection site reaction, immune reaction, worsen COPD | Injection site reaction, immune reaction | Injection site reaction, immune reaction |
| Special population considerations | Caution in pregnancy Hepatitis B or C, chronic liver disease Caution in kidney disease | Avoid pregnancy Hepatitis B or C, chronic liver disease Caution in kidney disease | Avoid pregnancy Hepatitis B or C, chronic liver disease | Avoid pregnancy Drug interactions | Avoid pregnancy Reactivation of TB, fungus, or viral infection Caution in kidney disease Approved for UC | Caution pregnancy Reactivation of TB, fungus, or viral infection Caution in CHF | Avoid pregnancy Avoid in hepatitis B Reactivation of TB, fungus, or viral infection | Avoid pregnancy Avoid in hepatitis B Reactivation of TB, fungus, or viral infection Drug interactions | Avoid pregnancy Avoid in hepatitis B Reactivation of TB, fungus, or viral infection Caution in IBD drug interactions |
| Safety monitoring plan (ACR guidelines) | Pretreatment: CXR, hepatitis B and C Labs every 1-3 months | Pretreatment: CXR, hepatitis B and C Labs every 1-3 months | Pretreatment: CXR, hepatitis B and C Labs every 1-3 months | No blood monitoring needed | Pretreatment: CXR, hepatitis B and C, TB test Labs every 3 months Yearly TB test | Pretreatment: CXR, hepatitis B and C, TB test Labs every 6 months Yearly TB test | Pretreatment: CXR, hepatitis B and C, TB test Labs every 6 months Yearly TB test | Pretreatment: CXR, hepatitis B and C, TB test Labs every 6 months Yearly TB test | Pretreatment: CXR, hepatitis B and C, TB test Labs every 6 months Yearly TB test |
| My monthly cost? | | | | | | | | | |

ACR=American College of Rheumatology. ACR20=American College of Rheumatology 20% response criteria. COPD=chronic obstructive pulmonary disease. CHF=congestive heart failure. CXR=chest X-ray. FDA=US Food and Drug Administration. IBD=inflammatory bowel disease. IL-12/23i=interleukin-12/23 inhibitor. IL-17=interleukin-17. JAK=janus kinase. PASI=Psoriasis Area and Severity Index. PDE4i=phosphodiesterase-4 inhibitor. RA=rheumatoid arthritis. TB=tuberculosis. TNF=tumor necrosis factor. UC=ulcerative colitis.
Updated: December 12, 2018 © Richard W. Martin, MD, MA. Free use for clinical care is permitted without license.

Facts and Numbers Behind This Decision Aid

FDA MEDICATION USER GUIDES

- Abatacept: https://packageinserts.bms.com/pi/pi_orencia.pdf
- Adalimumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125057s0110lbl.pdf
- Apremilast: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205437s000lbl.pdf
- Certolizumab pegol: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125160s283lbl.pdf
- Etanercept: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103795s5359lbl.pdf
- Golimumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125289s133lbl.pdf
- Infliximab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103772s5301MedG.pdf
- Ixekizumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125521s009lbl.pdf
- Leflunomide: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020905s020lbl.pdf
- Methotrexate: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/008085s066lbl.pdf
- Secukinumab: <https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf>
- Sulfasalazine: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/007073s124lbl.pdf
- Tofacitinib: <https://www.fda.gov/downloads/Drugs/DrugSafety/UCM330702.pdf>
- Ustekinumab: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf

COCHRANE DATABASE OF SYSTEMATIC REVIEWS

- Jones G, Crotty M, Brooks P. [Interventions for treating psoriatic arthritis \(review\)](#). Cochrane Database of Systematic Reviews, 2000, Issue 3. Art. No.: CD000212. DOI: 10.1002/14651858.CD000212.

OTHER PUBLICATIONS

- Coates LC, Kavanaugh A, Mease PJ, et al. [Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis](#). *Arthritis Rheumatol*. 2016;68:1060-1071.
- Coates LC, Kavanaugh A, Ritchlin CT; GRAPPA Treatment Guideline Committee. [Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA](#). *J Rheumatol*. 2014;41:2273-2276.
- Gossec L, Smolen JS, Ramiro S, et al. [European League Against Rheumatism \(EULAR\) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update](#). *Ann Rheum Dis*. 2016;75:499-510.
- Singh J, Guyatt G, Ogdie A, et al. [Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis](#). *Arthritis Rheumatol*. 2019;71(1):5-32.